IONS Form 4: CEO Brett Monia sold 437 shares under 10b5-1 plan

Rhea-AI Filing Summary

Brett P. Monia, Chief Executive Officer and Director of Ionis Pharmaceuticals (IONS), reported a sale of common stock under a pre-established Rule 10b5-1 trading plan. The report shows 437 shares were sold on 10/06/2025 at $69.2637 per share, leaving the reporting person with 179,572 shares beneficially owned after the transaction. The filing notes the 10b5-1 plan was adopted on 08/13/2024 and the Form 4 was signed via attorney-in-fact on 10/08/2025. The transaction is described as executed pursuant to the trading plan.

Insider Trade Summary

Net Seller: 437 shares ($30,268)

Net Sell 1 txn

Insider Monia Brett P

Role Chief Executive Officer

Sold 437 shs ($30K)

Type	Security	Shares	Price	Value
Sale	Common Stock	437	$69.2637	$30K

Holdings After Transaction: Common Stock — 179,572 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Monia Brett P

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CA 92010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/06/2025		S		437(1)	D	$69.2637	179,572	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 13, 2024.

	By: Patrick R. O'Neil, attorney-in-fact For: Brett P. Monia	10/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the IONS Form 4 filed for Brett P. Monia disclose?

The Form 4 disclosed a sale of 437 shares of Ionis Pharmaceutical common stock on 10/06/2025 at $69.2637 per share under a Rule 10b5-1 plan.

How many IONS shares does Brett P. Monia own after the reported sale?

179,572 shares beneficially owned following the reported transaction.

Was the sale executed under a Rule 10b5-1 trading plan for IONS?

Yes. The filing states the shares were sold pursuant to a Rule 10b5-1 trading plan adopted on 08/13/2024.

What is the transaction date and filing signature date on the IONS Form 4?

Transaction date: 10/06/2025. Form signature date: 10/08/2025 signed by an attorney-in-fact.

What title(s) does the reporting person hold at Ionis (IONS)?

Brett P. Monia is reported as both Chief Executive Officer and a Director of Ionis Pharmaceuticals.